{
    "pmcid": "8924699",
    "qa_pairs": {
        "How were the engineered Limosilactobacillus reuteri strains administered to chickens to reduce NE-associated mortality?": [
            "In ovo and via drinking water",
            "Through feed supplementation",
            "By direct injection into the bloodstream",
            "Via aerosolized spray in the environment"
        ],
        "What characteristic of nanobodies makes them suitable for oral delivery in therapeutic applications?": [
            "High stability and strong antigen-binding affinity",
            "Large size and complex structure",
            "Low stability and weak antigen-binding affinity",
            "Requirement for refrigeration and complex formulation"
        ],
        "What is the primary target of the nanobodies delivered by engineered Limosilactobacillus reuteri strains in the study?": [
            "Clostridium perfringens NetB and alpha toxin",
            "Clostridium difficile toxin A and B",
            "Escherichia coli enterotoxins",
            "Salmonella typhimurium endotoxins"
        ],
        "What potential broader application does the study suggest for the use of L. reuteri as a live vector for nanobody delivery?": [
            "Targeting viral infections like SARS-CoV-2",
            "Enhancing growth rates in livestock",
            "Improving gut microbiome diversity",
            "Increasing resistance to antibiotics"
        ],
        "Which technology was used to select high-affinity nanobodies specific to the toxins in the study?": [
            "Phage display technology",
            "CRISPR-Cas9 gene editing",
            "RNA interference",
            "Monoclonal antibody hybridoma technology"
        ]
    }
}